Last updated: May 29, 2026
VITRAKVI suppliers and manufacturing: who makes larotrectinib and what contract manufacturers supply
VITRAKVI (larotrectinib) is supplied through Bayer’s commercial chain and is manufactured by contract manufacturers for the active pharmaceutical ingredient (API) and finished dosage form. Public patent and corporate filings support that supply is routed through multiple vendors for API synthesis, formulation, and packaging, with quality control and regulatory release handled under Bayer’s market authorization holder obligations in each jurisdiction.
What companies supply larotrectinib (VITRAKVI) and contract manufacturers for API and tablets?
Executive answer: Public records tie VITRAKVI supply to Bayer leadership for market authorization and labeling, with API and finished product manufactured through external GMP vendors rather than a single vertically integrated site. The supply chain is multi-vendor by function: API manufacture, drug product manufacturing, and packaging/labeling.
API supply: who makes the larotrectinib active ingredient?
Larotrectinib API supply is typically performed by specialized API manufacturers with registered commercial production sites that support global filings. Publicly available supplier identification for exact named vendors is often limited to what appears in regulatory dossiers, which are not fully captured in public Orange Book-style feeds outside the US or in open-label resources.
Finished dosage form supply: who manufactures VITRAKVI capsules/solution?
VITRAKVI is sold in oral dosage forms (capsules and oral solution in key markets). Drug product is manufactured and packaged under GMP at contract manufacturing sites. Named sites and label-packaging partners are usually documented in marketing authorization applications and inspection databases, not in a single consolidated public list.
Packaging and secondary supply
Secondary packaging vendors (bottling, carton packaging, labeling) are generally contract partners under the drug product manufacturer’s batch release umbrella and are recorded in regulatory submissions per country.
How to map VITRAKVI suppliers using FDA, EMA, and drug master file sources?
Executive answer: Supplier mapping is done by cross-referencing (1) FDA/EMA product registries, (2) inspections and GMP site listings tied to Bayer release, and (3) DMF-based API sourcing where an API holder is named as a submitter. For VITRAKVI, the key gating factor is that Bayer controls product release even when manufacturing is outsourced.
FDA where supplier names can appear
In the US, the most reliable supplier identifiers typically come from:
- the drug product’s FDA submission history (Chemistry/CMC exhibits within the NDA),
- labeling and packaging instructions embedded in submission packages,
- and supplier-specific entries when Bayer relies on DMFs for API.
EMA where supplier names can appear
In the EU, supplier detail is usually captured in:
- the marketing authorization file,
- variations and manufacturing site updates,
- and GMP inspection outcomes.
Which VITRAKVI suppliers provide manufacturing sites for GMP and regulatory release?
Executive answer: GMP manufacturing sites are the primary “supplier” unit for regulatory purposes. For VITRAKVI, Bayer’s supply chain runs through qualified external sites that perform API synthesis and drug product manufacture, with Bayer as the holder of regulatory responsibility and final release.
What counts as a supplier in compliance terms
- API manufacturing site (GMP API synthesis)
- Drug product manufacturing site (capsule/solution manufacture)
- Packaging and labeling site (if different)
- Quality control testing site (can be internal or outsourced)
What patents or filings reveal VITRAKVI manufacturing vendors?
Executive answer: Patents for larotrectinib and its formulations rarely name full commercial manufacturing suppliers. What they can do is identify the process chemistry inventors, assignees, and sometimes generic manufacturing steps, but they usually do not provide contract manufacturer identities.
How to use patent assignees for supply-chain inference
- Identify assignees involved in process development.
- Track whether the same assignee appears as a manufacturing partner in later CMC exhibits or published quality agreements.
- Cross-check with manufacturing site registrations once known.
Are there multiple VITRAKVI suppliers across geographies?
Executive answer: Yes. Multi-site manufacturing and multi-vendor sourcing are common for small-molecule oncology drugs with global demand. Bayer’s commercial distribution for VITRAKVI typically uses at least two manufacturing configurations: one for API/drug product production and another for packaging.
US vs EU vs other regions
- US distribution aligns with US-registered manufacturing facilities.
- EU distribution aligns with EMA-accepted GMP sites.
- Other jurisdictions rely on local registration submissions that reference approved sites.
What generic entry risks change supplier leverage for VITRAKVI?
Executive answer: Supplier leverage changes if generic manufacturers introduce bioequivalent oral solid substitutes. However, VITRAKVI’s near-term supplier strategy is driven by Bayer’s API supply continuity and drug product capacity rather than by generic leverage unless supply shortages or regulatory constraints emerge.
Why suppliers matter in generic launches
- If a competitor needs the same API intermediate supply, leverage can come from DMF access or API control.
- Packaging and formulation IP can affect how easily a generic can source an equivalent finished product.
Key Takeaways
- VITRAKVI supply is operated through Bayer’s controlled regulatory chain with external GMP contract manufacturers for API and finished oral dosage forms.
- “Supplier” in a compliance sense is a registered GMP manufacturing site for API, drug product, and packaging, not just a branded distributor.
- Patent literature does not reliably disclose specific contract manufacturer names; supplier identification is usually accomplished through CMC/DMF and GMP site documentation tied to FDA/EMA submissions.
FAQs
Which company holds responsibility for VITRAKVI in the US and Europe?
Bayer is the market authorization holder and label owner for VITRAKVI, with manufacturing performed at qualified GMP sites.
Does VITRAKVI use a single API supplier or multiple?
VITRAKVI is generally supported by multi-site and multi-vendor GMP sourcing for continuity, but contract names are usually reflected in regulatory submissions rather than a single public directory.
Are contract manufacturers for larotrectinib different from packaging vendors?
Often yes. Drug product manufacturing and secondary packaging/labeling can be performed at separate qualified sites.
Can patents identify VITRAKVI manufacturing sites?
Patents rarely name commercial manufacturing vendors directly; they more commonly identify process concepts and assignees.
Where can I verify VITRAKVI manufacturing sites?
Verification is done through regulatory agency records tied to the approved drug product and GMP inspection outcomes, aligned to FDA and EMA submissions.
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
- EMA. VITRAKVI (larotrectinib): EPAR and related product information. European Medicines Agency.
- Bayer. VITRAKVI (larotrectinib) prescribing information and US labeling. Bayer; FDA label access.
